Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T-cells in a cell-free system

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4189-4202

  Jakka, Gopinadh ^a   Schuberth, Petra C ^a   Thiel, Markus ^b   Held, Gerhard ^b   Stenner, Frank ^a   Van Den Broek, Maries ^a   Renner, Christoph ^c   Mischo, Axel ^a   Petrausch, Ulf ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Anti idiotypic antibody; Chimeric antigen receptor; Expansion; NY ESO 1; Peptide specific; Redirected T cells

Indexed keywords

A 4 ANTIIDIOTYPIC FAB ANTIBODY; ANTIIDIOTYPIC ANTIBODY; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN RECEPTOR; NY ESO 1 ANTIGEN; TETRAMER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING COMPETITION; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL FREE SYSTEM; CELL PROLIFERATION; CELL PROTECTION; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTI-IDIOTYPIC ANTIBODY; CHIMERIC ANTIGEN RECEPTOR; EXPANSION; NY-ESO-1; PEPTIDE SPECIFIC; REDIRECTED T-CELLS;

ANIMALS; ANTIBODY AFFINITY; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL-FREE SYSTEM; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; TUMOR BURDEN;

EID: 84891365169     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111, 2001.
2. Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet MJ, Champagne P et al: Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 60: 4499-4506, 2000.
3. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D et al: Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187: 265-270, 1998.
4. Khong HT and Rosenberg SA: Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J Immunol 168: 951-956, 2002.
5. Korangy F, Ormandy LA, Bleck JS, Klempnauer J, Wilkens L, Manns MP et al: Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10: 4332-4341, 2004.
6. + helper T cell responses in cancer patients. Blood 106: 1008-1011, 2005.
7. Bonertz A, Weitz J, Pietsch DH, Rahbari NN, Schlude C, Ge Y et al: Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 119: 3311-3321, 2009.
8. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854, 2002.
9. Porter DL, Levine BL, Kalos M, Bagg A and June CH: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365: 725-733, 2011.
10. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME et al: Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29: 917-924, 2011.
11. Jena B, Dotti G and Cooper LJ: Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116: 1035-1044, 2010.
12. Kershaw MH, Teng MW, Smyth MJ and Darcy PK: Supernatural T cells: genetic modification of T cells for cancer therapy. Nat Rev Immunol 5: 928-940, 2005.
13. Cheadle EJ, Sheard V, Hombach AA, Chmielewski M, Riet T, Berrevoets C et al: Chimeric antigen receptors for T-cell based therapy. Methods Mol Biol 907: 645-666, 2012.
14. Hombach A, Heuser C, Gerken M, Fischer B, Lewalter K, Diehl V et al: T cell activation by recombinant FcepsilonRI gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition. Gene Ther 7: 1067-1075, 2000.
15. Hombach A, Sent D, Schneider C, Heuser C, Koch D, Pohl C et al: T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res 61: 1976-1982, 2001.
16. Chiu YL, Schneck JP and Oelke M: HLA-Ig based artificial antigen presenting cells for efficient ex vivo expansion of human CTL. J Vis Exp. 2011.
17. Durai M, Krueger C, Ye Z, Cheng L, Mackensen A, Oelke M et al: In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunol Immunother 58: 209-220, 2009.
18. Brimnes MK, Gang AO, Donia M, Thor Straten P, Svane IM and Hadrup SR: Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion. Cancer Immunol Immunother. 2012.
19. Li Y and Kurlander RJ: Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation. J Transl Med 8: 104, 2010.
20. Stewart-Jones G, Wadle A, Hombach A, Shenderov E, Held G, Fischer E et al: Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci USA 106: 5784-5788, 2009.
21. Schuberth PC, Jakka G, Jensen SM, Wadle A, Gautschi F, Haley D et al: Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther. 2012.
22. Held G, Matsuo M, Epel M, Gnjatic S, Ritter G, Lee SY et al: Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur J Immunol 34: 2919-2929, 2004.
23. de Haard HJ, van Neer N, Reurs A, Hufton SE, Roovers RC, Henderikx P et al: A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem 274: 18218-18230, 1999.
24. Chmielewski M, Hahn O, Rappl G, Nowak M, Schmidt-Wolf IH, Hombach AA et al: T Cells That Target Carcinoembryonic Antigen Eradicate Orthotopic Pancreatic Carcinomas Without Inducing Autoimmune Colitis in Mice. Gastroenterology. 2012.
25. Unsoeld H, Pircher H. Complex memory T-cell phenotypes revealed by coexpression of CD62L and CCR7. J Virol 79: 4510-4513, 2005.
26. Dent LA, Spencer LK, Attridge S and Finlay-Jones JJ: Differences in the phenotypes of cells mediating anti-tumour immunity at various stages of tumour progression in mice. Immunol Cell Biol 67(Pt 6): 403-412, 1989.
27. Nguyen LT, Yen PH, Nie J, Liadis N, Ghazarian D, Al-Habeeb A et al: Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs). PLoS One 5: e13940, 2010.
28. Zappasodi R, Di Nicola M, Carlo-Stella C, Mortarini R, Molla A, Vegetti C et al: The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. Haematologica 93: 1523-1534, 2008.
29. Klapper JA, Thomasian AA, Smith DM, Gorgas GC, Wunderlich JR, Smith FO et al: Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy. J Immunol Methods 345: 90-99, 2009.
30. Colja Venturini A, Bresjanac M, Vranac T, Koren S, Narat M, Popovic M et al: Anti-idiotypic antibodies: a new approach in prion research. BMC Immunol 10: 16, 2009.
31. Heuser C, Hombach A, Losch C, Manista K and Abken H: T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells. Gene Ther 10: 1408-1419, 2003.
32. Habib-Agahi M, Jaberipour M, Phan TT and Searle PF: Preferential T cell expansion by artificial antigen presenting cells expressing 4-1BBL alone or in combination with CD80 or CD86. Iran J Immunol 5: 136-147, 2008.
33. Rosenberg SA and Dudley ME: Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21: 233-240, 2009.
34. Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M and Yee C: White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res 17: 1664-1673, 2011.
35. Porter DL, Levine BL, Bunin N, Stadtmauer EA, Luger SM, Goldstein S et al: A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 107: 1325-1331, 2006.
36. Rasmussen AM, Borelli G, Hoel HJ, Lislerud K, Gaudernack G, Kvalheim G et al: Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. J Immunol Methods 355: 52-60, 2010.
37. Oelke M, Maus MV, Didiano D, June CH, Mackensen A and Schneck JP: Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 9: 619-624, 2003.
38. Kalamasz D, Long SA, Taniguchi R, Buckner JH, Berenson RJ and Bonyhadi M: Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies. J Immunother 27: 405-418, 2004.
39. Ye Q, Loisiou M, Levine BL, Suhoski MM, Riley JL, June CH et al: Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. J Transl Med 9: 131, 2011.
40. Miyakawa Y, Ohnishi Y, Tomisawa M, Monnai M, Kohmura K, Ueyama Y et al: Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice. Biochem Biophys Res Commun 313: 258-262, 2004.
41. van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P et al: NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 105: 3939-3944, 2005.
42. Rapoport AP, Stadtmauer EA, Vogl DT, Weiss BM, Binder-Scholl GK, Brewer JE et al: Adoptive Transfer of Gene-Modified T-Cells Engineered to Express High-Affinity TCRs for Cancer-Testis Antigens (CTAs) NY-ESO-1 or Lage-1, in MM Patients Post Auto-SCT. Blood 2012;120.